GlassScriptPhysician profile
Kerri A Bewick
NPI 1912103755
$9,820.14
in general payments reported to CMS, 2019-2025
35 companies · $2,301 in 2025
The $2,301 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $700 · 2021: $647 · 2022: $1,417 · 2023: $2,498 · 2024: $1,895 · 2025: $2,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,528 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,527.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $166.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,819.33 | 2021-2025 | Rinvoq, Linzess, Viberzi |
| Celgene Corporation | $1,340.71 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $995.05 | 2020-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $785.84 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $771.19 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $676.46 | 2019-2025 | |
| Qol Medical, LLC | $640.16 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $410.29 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $390.85 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $344.90 | 2021-2025 | Tremfya, Stelara |
| Genzyme Corporation | $237.28 | 2022-2025 | |
| Madrigal Pharmaceuticals | $152.36 | 2025 | Rezdiffra |
| Novo Nordisk INC | $140.32 | 2022-2025 | Wegovy |
| Aimmune Therapeutics, INC. | $129.08 | 2024-2025 | Vowst, Zenpep |
| E.R. Squibb & Sons, L.L.C. | $119.89 | 2023 | Zeposia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $108.93 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $102.37 | 2020-2024 | Ocaliva |
| Ardelyx, INC. | $94.15 | 2022-2025 | Ibsrela |
| Amgen INC. | $53.10 | 2022-2023 | Avsola, Amjevita |
| Ucb, INC. | $52.32 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $52.26 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $52.06 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $45.07 | 2021-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $42.19 | 2021-2023 | |
| Redhill Biopharma INC. | $35.28 | 2021-2022 | |
| Concordia Pharmaceuticals INC. | $34.09 | 2019 | |
| Daiichi Sankyo INC. | $32.36 | 2020-2022 | |
| Braintree Laboratories, INC. | $30.40 | 2019-2020 | |
| Exact Sciences Corporation | $23.58 | 2025 | The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $22.14 | 2021 | |
| Vivus LLC | $19.45 | 2025 | Qsymia |
| W. L. Gore & Associates, INC. | $17.75 | 2022 | |
| Lilly USA, LLC | $17.37 | 2024 | Omvoh |
| Romark Laboratories, Lc | $16.51 | 2020 | |
| Amag Pharmaceuticals, INC. | $15.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerri Bewick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.